CD80 and neoplasm: Tumor-specific T cells can be activated through recognition of a major histocompatibility complex (MHC)-bound cancer epitope by the T cell receptor (TCR) or the interaction between co-stimulatory receptors (e.g., CD28) on T cells and their corresponding ligands (e.g., B7 molecules) on activated antigen-presenting cells (34).